Anticoagulant Treatment of @entity1150 and XXXX : The Present State of the Art.

@entity1 @entity2067 @entity5 @entity1151 @entity1150 @entity715 @entity1211
@entity1211 ( @entity1211 ), a disease entity comprising @entity1150 ( @entity1150 ) and @entity1151 ( @entity1151 ), is a frequent and potentially life-threatening event. To date different agents are available for the effective treatment of acute @entity1211 and the prevention of recurrence. For several years, the standard of care was the subcutaneous application of a low molecular weight heparin (LMWH) or fondaparinux, followed by a @entity2067 antagonist (VKA). The so-called direct oral anticoagulants (DOAC) were introduced rather recently in clinical practice for the treatment of @entity1211 . DOAC seem to have a favorable risk-benefit profile compared to VKA. Moreover, DOAC significantly simplify @entity1211 treatment because they are administered in fixed doses and no routine monitoring is needed. @entity1 with objectively diagnosed @entity1150 or @entity1151 should receive therapeutic anticoagulation for a minimum of 3   months. Whether a @entity1 ought to receive extended treatment needs to be evaluated on an individual basis, depending mainly on risk factors determined by characteristics of the @entity715 event and @entity1 -related factors. In specific @entity1 groups (e.g., pregnant @entity1 , @entity5 @entity1 , and elderly @entity1 ), treatment of @entity1211 is more challenging than that in the general population and additional issues need to be considered in those @entity1 . The aim of this review is to give an overview of the currently available treatment modalities of acute @entity1211 and secondary prophylaxis. In particular, specific aspects regarding the initiation of @entity1211 treatment, duration of anticoagulation, and specific @entity1 groups will be discussed.
